𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Motor fluctuations and dyskinesias in advanced/end stage Parkinson’s disease: a study from a population of brain donors

✍ Scribed by S. Papapetropoulos; D. C. Mash

Publisher
Springer
Year
2006
Tongue
English
Weight
73 KB
Volume
114
Category
Article
ISSN
1435-1463

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dementia in Parkinson's disease: a post-
Dementia in Parkinson's disease: a post-mortem study in a population of brain donors
✍ S. Papapetropoulos; J. Gonzalez; A. Lieberman; J. M. Villar; D. C. Mash 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB 👁 1 views

## Abstract ## Objective To identify factors associated with dementia in a cohort of Parkinson's disease (PD) brain donors and determine whether its presence may influence the clinical phenotype of the disease. ## Methods We included 67 consecutive patients with a clinical and pathological diagn

Efficacy of long-term continuous subcuta
Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study
✍ Pedro J. García Ruiz; Ángel Sesar Ignacio; Begoña Ares Pensado; Alfonso Castro G 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

## Abstract Continuous subcutaneous apomorphine infusion (CSAI) is, at present, an alternative option for advanced Parkinson's disease (PD) with motor fluctuations. We studied the evolution of patients with PD and severe motor fluctuations long‐term treated with CSAI. We reviewed data from 82 patie

Study of istradefylline in patients with
Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
✍ Robert A. Hauser; Lisa M. Shulman; Joel M. Trugman; John W. Roberts; Akihisa Mor 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 1 views

## Abstract The objective of this study was to evaluate the efficacy, safety, and tolerability of istradefylline 20 mg once daily versus placebo as an adjunct to levodopa in subjects with Parkinson's disease (PD) who have motor fluctuations. Istradefylline (KW‐6002) is an adenosine A~2A~ receptor a